Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3893438 | 0.88 | DPP4 (0.65) | DPP4 | |
| Hydrochloric Acid SCHEMBL3890609 | 0.84 | DPP4 (0.68) | DPP4DPP9DPP8 | |
| SCHEMBL4019669 | 0.83 | DPP4 (0.56) | DPP4ALDH1A1DPP9DPP8RAB9A | |
| SCHEMBL3901983 | 0.80 | DPP4 (0.41) | DPP4DPP9DPP8 | |
| SCHEMBL3896594 | 0.80 | DPP4 (0.63) | DPP4ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3893687 | 0.78 | DPP4 (0.77) | DPP4ALDH1A1DPP9DPP8 | |
| SCHEMBL3895939 | 0.77 | DPP4 (0.56) | DPP4ALDH1A1DPP9DPP8RAB9A | |
| Hydrochloric Acid SCHEMBL3902203 | 0.76 | DPP4 (0.69) | DPP4DPP9DPP8 | |
| Hydrochloric Acid SCHEMBL3893765 | 0.75 | DPP4 (0.64) | DPP4DPP9DPP8 | |
| SCHEMBL3893923 | 0.74 | DPP4 (0.42) | DPP4DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547710-B2 | Fused heterocyclic compounds as peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1527049-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060135530-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135530-A1 | Fused heterocyclic compounds | NR4A3, DPP3, INSR | DPP4 13/4885ALDH1A1 2712/4885DPP9 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.